Business Wire

Revance Resubmits Biologics License Application for DaxibotulinumtoxinA for Injection for Glabellar Lines to the FDA

NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced it has resubmitted its ...
Dermatology Advisor

Repeat TrenibotulinumtoxinE Treatment Is Effective, Safe for Glabellar Lines

Repeat administration of trenibotulinumtoxinE is effective in reducing glabellar line severity, with no significant safety ...
Healio

Repeated injections of relabotulinumtoxinA safe long term for frown lines, crow’s feet

Please provide your email address to receive an email when new articles are posted on . 43.9% of patients experienced a treatment-emergent adverse event. Only 18.2% were treatment related. Efficacy ...
Business Wire

Revance Receives FDA Acceptance of BLA Resubmission for DaxibotulinumtoxinA for Injection for Glabellar Lines

NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that the U.S. Food and ...
Nasdaq

Healis Therapeutics' asset CKDB-501A shares Phase III topline results for glabellar injections from CKD Bio in South Korea

NEWPORT BEACH, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Healis Therapeutics, a privately held biotechnology company, is thrilled to share that strategic partner, Chong Kun Dang Bio (063160:Korea SE), ...